We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS Secretary Michael Leavitt has started shaping his senior leadership team,
announcing six key appointments to the agency, including the creation of a senior
health policy position.
Indian drugmaker Ranbaxy Pharmaceuticals scored a victory on the patent front
when the Austrian Patent Office (APO) invalidated a patent on Pfizer's cholesterol-lowering
drug Lipitor.
Aiming to rein in public spending on pharmaceuticals, California lawmakers plan
to consider a bill that would require drugmakers to pay the state a rebate for
costs of marketing life-saving drugs used in state assistance programs --
a proposal that critics contend treads on commercial speech rights.
Biovail Corporation announced today that a United States District Judge for
the District of Columbia has granted Biovail's motions for summary judgment,
thereby dismissing complaints in two related putative class-action cases asserting
antitrust claims by purchasers of Biovail's Tiazac product.
Inncardio, a company founded by Bioaccelerate Holdings, announced today a definitive
agreement to acquire Cengent Therapeutics Inc., a privately held, structure-guided
drug discovery company based in San Diego, CA. Inncardio is a biotechnology
company focused on the development of treatments and therapies targeted at cardiovascular-related
diseases.
Cellegy Pharmaceuticals said Tuesday its accountants will include a going concern
qualification in its annual 10-K financial report, and that it will seek to
raise money through partnership with other drug companies or through equity
or debt financing.
Abbott Laboratories and Geneva Pharmaceuticals have agreed to a $30.7 million
nationwide settlement to refund customers and third-party payers in 18 states
who claimed that the two companies had conspired to engage in anticompetitive
conduct selling a drug that treats hypertension and enlarged prostate.